FORM PTO-1449
(REV 2-32)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

File No. 02-24

Serial No.
10/691,923

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

several sheets if necessary)

Applicant(s):

Kevin M. Klucher, Pallavur V.
Sivakumar, Wayne R. Kindsvogel,
Katherine E. HendersonFiling Date:
October 23, 2003

Group: 1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FH	A1	2003/0104416	06/05/03	Sheppard et al.	435	6	
	A2	2004/0029228	02/12/04	Presnell et al.	435	69.1	
	A3	2002/0039763	04/04/02	Sheppard et al.	435	69.1	
	A4	2004/0138122	07/15/04	Klucher et al.	514	12	
	A5	5,206,344	04/27/93	Katre et al.	530	351	

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FH	A6	03/066002	08/14/03	WIPO			
	A7	02/086087	10/31/02	WIPO			
	A8	03/089603	10/30/03	WIPO			
	A9	02/20569	03/14/02	WIPO			
	A10	02/092762	11/21/02	WIPO			
	A11	0 032 134	07/15/81	EP			
	A12	04/037995	05/06/04	WIPO			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Patents, etc.)

FH	A13	Kotenko et al., "IFN-λs mediate antiviral protection through a distinct class II cytokine receptor complex," <i>Nature Immunology</i> 4(1):69-77, 2003.
	A14	Sheppard et al., "IL-28, IL-29 and their class II cytokine receptor IL-28R," <i>Nature Immunology</i> 4(1):63-68, 2003.
	A15	Langer et al., "The Class II cytokine receptor (CRF2) family: overview and patterns of receptor-ligand interactions," <i>Cytokine and Growth Factor Reviews</i> 15:33-48, 2004.
	A16	Donnelly et al., "The expanded family of class II cytokines that share the IL-10 receptor-2 (IL-10R2) chain," <i>J. Leukocyte Biol.</i> 76:314-321, 2004.
	A17	Dumoutier et al., "Role of the Interleukin (IL)-28 Receptor Tyrosine Residues for Antiviral and Antiproliferative Activity of IL-29/Interferon-λ1," <i>J. Biochem.</i> 279(31):32269-32274, 2004.
	A18	University Calif. Santa Cruz Genome Browser - Chromosome 19, April 20, 2001.

Examiner

Date considered

1/6/06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1019
(REV 2-32) U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

File No. 02-24

Serial No.
10/691,923

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant(s):

Kevin M. Klucher, Pallavur V.
Sivakumar, Wayne R. Kindsvogel,
Katherine E. Henderson

Filing Date:
October 23, 2003

Group: 1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
---------------------	--------------------	------	------	-------	----------	-------------------------------


FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
---------------------	--------------------	------	---------	-------	----------	-------------------------------

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Patents, etc.)

FH	A19	University Calif. Santa Cruz Genome Browser Database – August 6, 2001, Accession No. C19001210.
	A20	University Calif. Santa Cruz Genome Browser Database – August 6, 2001, Accession No. C19001212.
	A21	University Calif. Santa Cruz Genome Browser Database – August 6, 2001, Accession No. C19001213.
	A22	University Calif. Santa Cruz Genome Browser Database – December 22, 2001, Accession No. C19001260.
	A23	University Calif. Santa Cruz Genome Browser Database – December 22, 2001, Accession No. C19001256.
	A24	University Calif. Santa Cruz Genome Browser Database – December 22, 2001, Accession No. C19001257.
	A25	Ensembl Contig. View Sanger Institute – April 19, 2001, Accession No. AC011445.
	A26	Ensembl Contig. View Sanger Institute – April 18, 2000, Accession No. AC018477.
	A27	Adams et al., "3,400 expressed sequence tags identify diversity of transcripts from human brain," <i>Nat. Genet.</i> 4:256-267, 1993.
	A28	GenBank Submission XP-002202436, October 12, 2000.
	A29	GenBank Submission XP-002202437, December 12, 1999.
	A30	Kindsvogel et al., "Novel Interferon-Like Cytokines not Recognized by the Type I Interferon Receptor," <i>J. Interferon Cytokine Res.</i> 22(1):S-48, 2002.
	A31	Adams et al., Accession No. T07139, 1993.
	A32	DOE Joint Genome Institute Stanford Human Genome Center, Accession No. AC011445, 1999.
	A33	Muzney et al., Accession No. AC007458, 1999.

Examiner



Date considered

1/9/06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO 1449 (REV 2-32)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	File No. 02-24	Serial No. 10/691,923
		Applicant(s): Kevin M. Klucher, Pallavur V. Sivakumar, Wayne R. Kindsvogel, Katherine E. Henderson	
		Filing Date: October 23, 2003	Group: 1646

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
---------------------	--------------------	------	------	-------	----------	-------------------------------

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
---------------------	--------------------	------	---------	-------	----------	-------------------------------

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Patents, etc.)

FH	A34		University of California Santa Cruz database using Softberry, Inc. gene prediction software, Accession No. C19001084, 2001.
I	A35		Scott et al., "The Pendred syndrome gene encodes a chloride-iodide transport protein," <i>Nature Genetics</i> , 21:440-443, 1999.
	A36		Korba et al., "A cell culture assay for compounds which inhibit hepatitis B virus replication," <i>Antiviral Research</i> 15:217-228, 1991.
	A37		Brack et al., "Molecular analysis of the human interferon- α gene family," <i>Gene</i> 15:379-394, 1981.
	A38		Francis et al., "PEGylation of cytokines and other therapeutic proteins and peptides: the importance of biological optimization of coupling techniques," <i>International Journal of Hematology</i> , 68(1):1-18, 1998.
	A39		Rajaratnam et al., "Disulfide Bridges in Interleukin-8 Probed Using Non-Natural Disulfide Analogues: dissociation of Roles in Structure from Function," <i>Biochemistry</i> 38:7653-7658, 1999.
	A40		Luxon et al., "Pegylated Interferons for the Treatment of Chronic Hepatitis C Infection," <i>Clinical Therapeutics</i> 24(9):1363-1383, 2002.
	A41		Kozlowski et al., "Improvements in protein OEGylation: pegylated interferons for treatment of hepatitis C," <i>Journal of Controlled Release</i> 72:217-224, 2001.
	A42		Goodson et al., "Site-Directed Pegylation of Recombinant Interleukin-2 at its Glycosylation Site," <i>BioTechnology</i> 8(4):343-346, 1990.
V	A43		Pettit et al., "Structure-Function Studies of Interleukin 15 using Site-specific Mutagenesis, Polyethylene Glycol Conjugation, and Homology Modeling," <i>J. Biochem</i> 272(4):2312-2318, 1997.

Examiner <i>for Hand</i>	Date considered 1/9/06
-----------------------------	---------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[illegible]